Company Profile

Acorda Therapeutics Inc
Profile last edited on: 12/3/2023      CAGE: 305Q1      UEI: R5D3FUPFFPK4

Business Identifier: Neurology therapies for Parkinson's disease, migraine and multiple sclerosis
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

2 Blue Hill Plaza 3rd Floor
Pearl River, NY 10965
   (914) 347-4300
Location: Multiple
Congr. District: 17
County: Westchester

Public Profile

Acorda Therapeutics is a biotechnology company focused on developing therapies that improve the lives of people with neurological disorders. Acorda markets three FDA-approved therapies including: AMPYRA® (dalfampridine), a treatment to improve walking in patients with multiple sclerosis (MS), as demonstrated by an increase in walking speed; ZANAFLEX , a short-acting drug for the management of spasticity; and QUTENZA® (capsaicin), for the management of neuropathic pain associated with postherpetic neuralgia. AMPYRA is marketed outside the United States as FAMPYRA® by Biogen Idec under a licensing agreement from Acorda. Acorda has one of the leading pipelines in the industry of novel neurological therapies. Since 2012, the firmhas made three acquisitions

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2005 1 NIH $184,388
Project Title: Molecular Evolution of Chondroitinase ABCI for SCI
2005 1 NIH $156,491
Project Title: Effects of Chondroitinase and Training in Acute SCI
2005 1 NIH $153,151
Project Title: Chimeric proteins for the treatment of spinal cord injury
2004 2 NIH $1,220,876
Project Title: Human Monoclonal Antibodies for CNS Regeneration
2003 1 NIH $107,300
Project Title: Release Chondroitinase Systems for Spinal Cord Injury

Key People / Management

  Ron Cohen -- CEO

  Andrew R Blight

  Anthony O Caggiano

  Eric W Chojnicki

  Anindita Ganguly

  Martin H Grumet

  Magdalena Hofer

  Timothy J Neuberger

  Moses Rodriquez

  Shuguang Zhang